跳至主要内容
临床试验/NCT00036062
NCT00036062已完成1 期

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

Eli Lilly and Company109 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2001年8月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
600
试验地点
109

研究概览

简要总结

The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.

详细描述

Acute lung injury often develops as a result of severe infection, sepsis, severe injuries, inhalation of foreign substances into the lungs, or pneumonia. The tissues and blood vessels in the lungs become inflamed, and the body does not receive enough oxygen. Patients with this condition are placed on a ventilator to assist with breathing.

Patients entered into this study will be randomly assigned to one of two treatment groups: a sivelestat group or a placebo group. Once entered into the study, patients are monitored for up to 6 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •show evidence of acute lung injury
  • •be on mechanical ventilation

排除标准

  • •have undergone certain organ transplants
  • •have severe underlying medical problems
  • •be unlikely to survive
  • •be pregnant or breast-feeding

研究者

申办方类型
Industry

研究点 (109)

Loading locations...

相似试验